DEF: TherapeuticsMD Sets 2025 Annual Meeting Agenda

TherapeuticsMD, Inc. announced its Annual Meeting of Stockholders for December 15, 2025, to vote on director elections, executive compensation, auditor ratification, and a significant increase in authorized common stock.

Summary

• The Annual Meeting of Stockholders is scheduled for December 15, 2025, at 8:00 a.m. Eastern Time, and will be held virtually via live webcast.
• The record date for stockholders entitled to vote at the meeting is October 20, 2025, with 11,574,362 shares of common stock outstanding.
• Key proposals include the election of four directors, a non-binding advisory vote on named executive officer compensation for fiscal year 2024 (Say-on-Pay), and a non-binding advisory vote on the frequency of future Say-on-Pay votes (Say-on-Frequency).
• Stockholders will also vote on the ratification of Berkowitz Pollack Brant Advisors + CPAs, LLP as the independent auditor for fiscal year 2025.
• A significant proposal is the approval of an amendment to increase the number of authorized shares of common stock from 32,000,000 shares to 640,000,000 shares.
• Net income for 2024 was $(2,181) thousand, an improvement from $(10,278) thousand in 2023, but still a loss.
• The Total Shareholder Return (TSR) for a $100 investment from December 31, 2021, to December 31, 2024, was $1.70, indicating substantial value erosion.
• The Board of Directors unanimously recommends voting FOR all proposals (1, 2, 4, 5) and FOR a 'one year' frequency for the Say-on-Pay vote (3).

Sentiment

Score: 3

Explanation: While a routine proxy statement, the underlying financial performance (negative net income, abysmal TSR) and the historical 'going concern' warning from the previous auditor are significant negatives. The proposed massive increase in authorized shares, while framed as strategic flexibility, also carries a high risk of substantial dilution for existing shareholders, especially given the company's poor past performance. The lack of Compensation Committee meetings in 2024 is also a governance concern.

Positives

• Net income improved from a loss of $(10,278) thousand in 2023 to a loss of $(2,181) thousand in 2024, indicating a reduction in losses.
• The company is seeking to increase authorized shares to provide flexibility for future capital raises, acquisitions, and strategic partnerships, which could support long-term growth initiatives.
• All current directors are independent, meeting Nasdaq listing requirements, which strengthens corporate governance.
• The company has adopted a clawback policy for incentive compensation and anti-hedging/anti-pledging policies, enhancing accountability and risk management.
• The Audit Committee actively oversees financial reporting and internal controls, holding five meetings in 2024.

Negatives

• The company reported a net loss of $(2,181) thousand in 2024, continuing a trend of negative profitability, despite an improvement from 2023.
• Total Shareholder Return (TSR) based on an initial $100 investment on December 31, 2021, significantly declined to $1.70 by December 31, 2024, indicating substantial shareholder value destruction.
• The previous independent auditor, Grant Thornton LLP, included an explanatory paragraph in its reports for fiscal years 2021 and 2022 describing uncertainty about the company's ability to continue as a going concern.
• The Compensation Committee held zero meetings during the fiscal year ended December 31, 2024, which may raise concerns about oversight of executive compensation.
• Only two of the company's directors virtually attended the 2024 annual meeting of stockholders.

Risks

• **Dilution Risk**: The proposed increase in authorized common stock to 640,000,000 shares could lead to significant dilution of existing stockholders' proportionate ownership and earnings per share if new shares are issued.
• **Anti-Takeover Effect**: The issuance of additional shares could make it more difficult for a third party to acquire control of the company, potentially discouraging offers that might be beneficial to stockholders.
• **Going Concern Uncertainty**: The previous auditor's reports for 2021 and 2022 included an explanatory paragraph regarding the uncertainty of the company's ability to continue as a going concern, suggesting ongoing financial challenges.
• **Market Price Volatility**: The market price of common stock is subject to performance and other factors unrelated to the number of shares outstanding, implying potential volatility.
• **Executive Compensation Risk**: The Compensation Committee considers risks that compensation policies and practices may have in attracting, retaining, and motivating valued employees, aiming to assure that plans do not create undue risk or have a material adverse effect on the company.

Future Outlook

The company aims to increase authorized common stock to provide flexibility for future capital raises, business expansion through acquisitions, and establishing strategic partnerships. The Board recommends an annual advisory vote on executive compensation to ensure timely feedback. Representatives of the independent auditor, Berkowitz Pollack Brant, are expected to be present at the annual meeting to address questions.

Management Comments

• "We believe this process [mailing Notice of Internet Availability of Proxy Materials] will allow us to provide our stockholders the information they need in a more timely manner, while reducing the environmental impact and lowering our costs of printing and delivering the proxy materials."
• "We appreciate your continued support of our Company."
• "Our Board of Directors believes that our current leadership structure provides the most effective leadership model for our Company, as it promotes balance between the Board of Directors independent authority to oversee our business and the Chief Executive Officer and his management team, which manage the business on a day -to-day basis."
• "Our Board of Directors believes that the information provided within the Executive Compensation section of this proxy statement demonstrates our executive compensation program is designed appropriately and is working to ensure our NEOs receive the majority of their compensation based on performance -driven considerations and that managements interests are aligned with our stockholders interests to support long -term value creation."
• "Our Board of Directors believes that an annual advisory vote of on executive compensation would be the most meaningful for our Board of Directors and our Compensation Committee and best serve the interests of our company and its stockholders."
• "Our Board of Directors believes that the authorized number of shares of common stock should be increased as a matter of good corporate governance to provide sufficient shares for such corporate purposes as may reasonably be determined by the Board of Directors to be necessary and in the best interest of our Company and stockholders."

Industry Context

The company operates within the biopharmaceutical and healthcare industry, as indicated by the expertise of its directors in regenerative medicine, FDA-approved products, and healthcare policy. The need for significant capital flexibility, as evidenced by the proposed increase in authorized shares, is common in this sector to fund research and development, clinical trials, market expansion, and potential acquisitions. The emphasis on robust corporate governance, executive compensation oversight, and auditor independence aligns with standard practices for publicly traded companies in highly regulated industries.

Comparison to Industry Standards

• The company's executive compensation program is designed to be competitive with similarly situated companies, though no specific industry benchmarks or comparable companies are named in the filing.
• The Total Shareholder Return (TSR) of $1.70 on a $100 investment over three years (2021-2024) represents an extremely poor performance, likely significantly underperforming most industry peers and broader market indices.
• The previous auditor's 'going concern' explanatory paragraph for 2021 and 2022 indicates a level of financial distress that is generally not typical for healthy, publicly traded companies in the biopharmaceutical sector.

Management Changes

Corporate Governance

Related Party Transactions

• **Rubric Capital Management LP**: Justin Roberts, a director, is a Partner at Rubric. He has elected not to receive director compensation. The company entered into multiple subscription agreements with Rubric in 2022 and 2023, including redeeming 29,000 shares of Series A Preferred Stock for $1,333 per share and paying $3.0 million as a make-whole payment to Rubric affiliates in December 2022. In 2023, the company issued 312,525 shares of Common Stock for $1.15 million and 877,192 shares for $2.0 million to Rubric. As of October 20, 2025, Rubric beneficially owns 2,946,908 shares (25.5%) of common stock.
• **JZ Advisory Group**: Joseph Ziegler, the company's Principal Financial and Accounting Officer, is the founder and CEO of JZ Advisory Group. The company entered into a Master Services Agreement with JZ Advisory on August 15, 2023, for Mr. Ziegler's services, with a monthly payment of $10,000.

Stakeholder Impact

• **Shareholders**: Face potential significant dilution from the proposed increase in authorized common stock. Have the opportunity to vote on key corporate governance matters and executive compensation. Have experienced substantial value destruction as indicated by the poor historical Total Shareholder Return.
• **Executive Officers**: Their compensation is subject to an advisory Say-on-Pay vote. Employment agreements provide for severance and benefits upon termination or change in control. They are subject to new clawback, anti-hedging/anti-pledging, and insider trading policies.
• **Employees**: Marlan Walker is the only full-time executive employee. Employees are eligible for general employee benefit plans, including medical, dental, and 401(k) match.
• **Auditor (Berkowitz Pollack Brant)**: Their appointment for fiscal year 2025 is subject to stockholder ratification. They receive audit fees for their services.

Next Steps

• Stockholders will vote on director elections, executive compensation, auditor ratification, and the authorized share increase at the Annual Meeting on December 15, 2025.
• The Board of Directors will consider stockholder input from the non-binding advisory votes on executive compensation and its frequency.
• If Proposal Five (Share Increase) is approved, the company intends to file the Certificate of Amendment to Articles of Incorporation promptly.
• Stockholders interested in submitting proposals for the 2026 annual meeting must do so by July 6, 2026, for inclusion in proxy materials, or by October 16, 2026, for director nominees under universal proxy rules.

Key Dates

Recommendation

The company's financial performance is concerning, marked by a net loss in 2024 and an extremely poor Total Shareholder Return (TSR) of $1.70 on a $100 investment over three years. The historical 'going concern' warning from the previous auditor further underscores financial instability. The proposal to increase authorized common stock by 20 times (from 32 million to 640 million shares) presents a substantial risk of significant shareholder dilution, especially given the company's past performance and the absence of clear, immediate, value-accretive plans for such a large issuance. While the board cites strategic flexibility, the magnitude of the increase suggests a high likelihood of future equity raises that could further depress share value. The lack of Compensation Committee meetings in 2024 also raises questions about governance oversight. Given these factors, a seasoned investor would likely view this as a high-risk investment with significant downside potential, warranting a 'sell' recommendation.

Keywords

TherapeuticsMD, TXMD, Proxy Statement, Annual Meeting, Stockholder Vote, Director Election, Executive Compensation, Say-on-Pay, Say-on-Frequency, Auditor Ratification, Authorized Shares Increase, Common Stock Dilution, Corporate Governance, SEC Filing, Financial Performance, Net Income, Shareholder Return, Biopharmaceutical, Healthcare, Risk Management